# A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

> **NCT01451164** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 459 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** OPC-34712
- **DRUG:** OPC-34712
- **DRUG:** OPC-34712
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01451164
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-06
- **Final completion:** —
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2019-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451164, "A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01451164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*